Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (776 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: cancerpurpose ofthe purposeevidencestudy is
  Phrases that lowered it: healthythe pharmacokineticskgsubjectsbody
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 15% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Primary purpose: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 384 (raises risk) · Sponsor's track record
• Responsible party: not given (raises risk) · Design
• Blinding: none (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 740 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Keywords listed: 0 (raises risk) · Design
• Disease area, psychiatry: No (lowers risk) · Disease area
• Maximum age: 45 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Combined Oral Contraceptive Effects in Female Subjects NCT02157467 · started 2014 · scored riskier than 4% of active trials completed
• A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants NCT05985590 · started 2023 · scored riskier than 2% of active trials completed
• A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI) NCT02480881 · started 2015 · scored riskier than 2% of active trials completed
• Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol NCT02533427 · started 2015 · scored riskier than 2% of active trials completed
• Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive NCT07215806 · started 2022 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.